Medicare’s $50 GLP-1 Bridge: Can You Get Wegovy or Zepbound?

Starting July 1, 2026, some people with Medicare drug coverage can get certain GLP-1 weight-loss medicines for $50 a month through a temporary federal program called the Medicare GLP-1 Bridge.

But the short answer is still: maybe, not automatically. Whether you can get Wegovy or Zepbound for $50 depends on your Medicare drug coverage, why the drug is being prescribed, and whether your prescriber can document that you meet the bridge rules.

Quick answer: Wegovy is included. Zepbound is included only as KwikPen. The program is available nationwide, but not every Medicare beneficiary qualifies, and the bridge works differently from regular Medicare Part D coverage.

What changed on July 1, 2026?

CMS launched the Medicare GLP-1 Bridge on July 1, 2026. It is a short-term demonstration that runs through December 31, 2027. The goal is to give some Medicare Part D beneficiaries access to certain GLP-1 drugs used for weight management at a fixed monthly copay.

This is an important detail: the bridge runs outside the normal Medicare Part D coverage and payment flow. That means it is not the same as having the drug covered through your regular Part D plan, and the $50 bridge copay does not behave like normal Part D spending.

Can you get Wegovy or Zepbound for $50?

Yes, if you qualify. Medicare says the bridge covers:

Foundayo tablets
Wegovy injections and tablets
Zepbound KwikPen

The bridge does not cover single-dose Zepbound vials or single-dose Zepbound pens.

If you qualify, you pay $50 to the pharmacy for a one-month supply. Medicare says that means 28 or 30 days, depending on the drug.

Who qualifies?

At a basic level, Medicare says you must have Medicare Part D drug coverage in an eligible plan type, be 18 or older, and be using the drug to reduce excess body weight or maintain weight reduction as part of an ongoing lifestyle program that includes nutrition and physical activity.

Eligible plan types include:

A standalone Medicare prescription drug plan
A Medicare Advantage coordinated care plan with drug coverage, including HMO, HMOPOS, and local or regional PPO plans
A Special Needs Plan
An employer or union group waiver plan
The Limited Income Newly Eligible Transition, or LI NET, program

CMS also says people who have both Medicare and Medicaid can use the bridge if they are in an eligible Part D plan and meet the prior-authorization criteria.

The clinical rules are where readers need to be careful. CMS’s provider instructions say the prescriber must attest that, when GLP-1 therapy started, the patient met one of these paths:

BMI 35 or higher, or
BMI 30 or higher plus heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or higher, or
BMI 27 or higher plus prediabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease

One practical point matters a lot for current users: CMS says the key BMI is the BMI you had when GLP-1 therapy began, not necessarily the BMI you have today. So if your weight has already come down, your prescriber may still be able to document that you met the rule when treatment started.

Important note for readers: the beneficiary-facing Medicare.gov checker groups some of the condition lists a little differently. On that page, people with a BMI of 30 to 34.99 may also see prediabetes, prior heart attack or stroke, and symptomatic peripheral artery disease listed as qualifying conditions. If you are in that BMI range, do not guess based on one summary alone. Use the official Medicare.gov checker and ask your prescriber to review the current CMS prior-authorization criteria.

Who may not qualify?

You may not qualify for the bridge if:

You already get your GLP-1 drug covered through your regular Medicare Part D plan
Your GLP-1 is being prescribed for a diagnosis that Medicare already treats as a regular Part D coverage pathway, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)
You are enrolled only in an excluded arrangement, such as a private fee-for-service plan, PACE, a fallback plan, a section 1876 cost contract plan, a section 1833 health care prepayment plan, or a religious fraternal benefit plan, unless you also have an eligible standalone drug plan

That middle point is easy to miss. If Medicare already covers your GLP-1 through regular Part D for another approved diagnosis, CMS says you should generally stay in that standard Part D pathway instead of switching to the bridge.

How coverage works in real life

The bridge is not something you sign up for by yourself online. It starts with your prescriber and your pharmacy.

Your clinician sends a prescription for a covered bridge drug to the pharmacy.
When requested, your clinician completes a prior authorization and certifies that you meet the bridge criteria and are using the drug as part of a lifestyle program focused on diet and exercise.
Your pharmacy may ask for your Medicare Number or the last four digits of your Social Security number to help process the prescription.
If approved, you should get a letter saying your GLP-1 is covered under the Medicare GLP-1 Bridge.

Medicare.gov says that once approved, the prior authorization stays valid for refills and dose changes through December 31, 2027, unless you switch to a different GLP-1 drug.

What the $50 copay means — and what it does not mean

The headline is real: if you qualify, you pay a fixed $50 monthly copay for a one-month supply. That is notable because JAMA reported that list prices for these medicines are often upward of $1,000 per month.

But the $50 price comes with limits. Medicare says the bridge copay:

Does not count toward your yearly Part D deductible
Does not count toward your Part D out-of-pocket limit
Will not appear on your Part D Explanation of Benefits
Will not appear on a Medicare Summary Notice
Cannot be lowered by Extra Help
Cannot be spread across months using the Medicare Prescription Payment Plan

So the bridge may lower what you pay at the pharmacy counter, but it does not work like ordinary Part D drug spending.

Safety still matters

Even if the cost is lower, these are still prescription medicines with real risks. MedlinePlus says common side effects can include nausea, vomiting, diarrhea, abdominal pain, loss of appetite, constipation, headache, and injection-site reactions. Rare but serious problems can include pancreatitis and gallbladder disease.

Seek urgent help right away for symptoms of a severe allergic reaction, such as trouble breathing, trouble swallowing, chest tightness, or hives. Contact your health care provider if side effects are bothering you. Do not start, stop, or switch a GLP-1 medicine based only on news coverage or a price change.

What readers can do next

Check your plan type. The bridge is only for certain people with Medicare Part D drug coverage.
Confirm the reason for the prescription. Bridge access is for weight management use, not for diagnoses that already belong in regular Part D coverage.
Ask about your starting BMI. If you began treatment before July 1, 2026, your earlier BMI may be the number that matters.
Verify the exact product. Wegovy is included, but Zepbound coverage is limited to KwikPen under this bridge.
Expect prior authorization. Your prescriber has to document eligibility.
Use the official Medicare.gov checker or call 1-800-MEDICARE if you are unsure whether the bridge may apply to you.

The bottom line: some Medicare beneficiaries really can get Wegovy or Zepbound for $50 a month starting July 1, 2026 — but only if they meet the bridge’s rules, use a covered product, and make it through the prior-authorization process.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.